Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider Xadago®‡ (safinamide), Inbrija™‡ (levodopa), Nourianz™‡ (istradefylline), Kynmobi™‡ (apomorphine hydrochloride), Apokyn®‡ (apomorphine hydrochloride), or Ongentys®‡ (opicapone) to be eligible for coverage when the patient selection criteria are met.

Patient Selection Criteria

Coverage eligibility for Xadago (safinamide), Inbrija (levodopa), Nourianz (istradefylline), Kynmobi (apomorphine hydrochloride), Apokyn (apomorphine hydrochloride), or Ongentys (opicapone) will be considered when the following criteria are met:

- For Xadago, Inbrija, Nourianz, or Ongentys requests:
  - Patient has a diagnosis of Parkinson disease; AND
  - Patient is currently being treated with levodopa/carbidopa and is experiencing “off” episodes; AND
  - Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following alternatives: generic pramipexole, generic ropinirole, generic entacapone, generic selegiline, or generic rasagiline unless there is clinical evidence or patient history that suggests the use of the alternative products will be ineffective or cause an adverse reaction to the patient.
    (Note: This specific patient criterion is an additional company requirement for coverage eligibility and will be denied as not medically necessary if not met.)

- For Apokyn or Kynmobi requests:

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 1 of 13
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy #  00603
Original Effective Date:  01/17/2018
Current Effective Date:  12/12/2022

- Patient has a diagnosis of Parkinson disease; AND
- Patient is currently being treated with levodopa/carbidopa and is experiencing “off” episodes; AND
  (Note: The requirement that the patient is currently being treated with levodopa/carbidopa is an additional company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Patient has tried and failed (e.g., intolerance or inadequate response) ONE of the following alternatives: generic pramipexole, generic ropinirole, generic entacapone, generic selegiline, or generic rasagiline unless there is clinical evidence or patient history that suggests the use of the alternative products will be ineffective or cause an adverse reaction to the patient.
  (Note: This specific patient criterion is an additional company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Xadago (safinamide), Inbrija (levodopa), Nourianz (istradefylline), or Ongentys (opicapone) when the patient has not tried and failed at least two alternative products listed in the patient selection criteria to be not medically necessary.**

Based on review of available data, the Company considers the use of Apokyn (apomorphine hydrochloride) or Kynmobi (apomorphine hydrochloride) when the patient has not tried and failed at least one alternative product listed in the patient selection criteria to be not medically necessary.**

Based on review of available data, the Company considers the use of Kynmobi (apomorphine hydrochloride) or Apokyn (apomorphine hydrochloride) when the patient is not currently being treated with levodopa/carbidopa to be not medically necessary.**

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers Xadago (safinamide), Inbrija (levodopa), Nourianz (istradefylline), Kynmobi (apomorphine hydrochloride), Apokyn (apomorphine hydrochloride), or Ongentys (opicapone) for the treatment of any indication other than “off” episodes in Parkinson disease to be investigational.*

Based on review of available data, the Company considers Xadago (safinamide), Inbrija (levodopa), Nourianz (istradefylline), or Ongentys (opicapone) in patients who are not currently being treated with levodopa/carbidopa to be investigational.*

Background/Overview

Xadago is a reversible inhibitor of monoamine oxidase B (MAO-B) that is used to prevent the degradation of dopamine and prevent “off” episodes in patients with Parkinson disease managed by levodopa/carbidopa. It is available as a 50 mg and 100 mg tablet and dosed 50 or 100 mg once daily. Unlike the other MAO-B inhibitors, selegiline and rasagiline, Xadago inhibits MAO-B reversibly. It is contraindicated in severe hepatic impairment and when administered concomitantly with any other MAO inhibitor (including linezolid), opioid drugs, serotonin-norepinephrine receptor inhibitors (SNRIs), tricyclic, tetracyclic, or triazolopyridine antidepressants, cyclobenzaprine, methylphenidate, amphetamine derivatives, St. John’s Wort, and dextromethorphan.

Inbrija is an inhaled formulation of levodopa and is indicated to treat “off” episodes in patients with Parkinson disease managed by levodopa/carbidopa. The contents of two 42 mg capsules should be inhaled as needed, up to 5 times a day. The maximum dose per “off” period is 84 mg (2 capsules) and the maximum daily dose is 420 mg. Like Xadago, Inbrija is also contraindicated in patients taking nonselective MAO inhibitors.

Nourianz is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes. It is dosed as 20 mg once daily, but the dose can be increased to 40 mg once daily if needed. The safety profile of
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

Nourianz is comparable to other therapies for this indication, but the long-term safety and efficacy has not yet been determined.

Kynmobi and Apokyn both contain apomorphine, which is a non-ergoline dopamine agonist. Kynmobi is indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson disease and is dosed as 10-30 mg sublingually as needed. Apomorphine is also available in injectable form as Apokyn which is indicated for the acute, intermittent treatment of hypomobility, “off” episodes associated with advanced Parkinson disease. Apokyn should be initially dosed as 0.2 mL (2 mg) subcutaneously as needed with doses increased in 0.1 mL (1 mg) increments every few days on an outpatient basis. Both Kynmobi and Apokyn should be co-administered with trimethobenzamide to control nausea and vomiting. Doses of both products should be separated by at least 2 hours with a maximum of 5 doses per day. The prescribing information for both products states that the initial dose should be supervised by a healthcare provider. Dose titrations of Kynmobi also require monitoring by a healthcare provider.

Ongentys is a catechol-o-methyltransferase (COMT) inhibitor indicated for adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes. It should be dosed as 50 mg by mouth once daily at bedtime. Generically available COMT inhibitors include entacapone and tolcapone, both of which carry the same indication. The possible advantage of Ongentys over these generic products is that it is dosed less frequently. However, Ongentys has not been studied in comparison to these other products. Additionally, these generically available treatment options may provide a more economical and equally efficacious treatment option.

Parkinson disease is a progressive neurodegenerative disease in which dopamine depletion from the basal ganglia results in disruptions in the connections to the thalamus and motor cortex. For most patients, first line therapy involves supplementation of dopamine via levodopa/carbidopa. As the disease progresses, periods of increased symptoms known as “off” episodes can occur when levodopa/carbidopa begins to wear off between doses. Initially, these episodes may be managed by adjusting the levodopa/carbidopa dose and schedule, but this may not be sufficient if the patient is experiencing adverse effects of the levodopa/carbidopa (such as dyskinesia). There are four classes of drugs indicated as adjunctive therapy to manage “off” episodes with levodopa/carbidopa: dopamine agonists, catecholamine-O-methyltransferase (COMT) inhibitors, MAO-B inhibitors, and adenosine receptor antagonists. Dopamine agonists such as pramipexole or ropinirole can be effective at prolonging symptom-free periods, but patients must be monitored for excessive
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

dopaminergic effects (hallucinations, confusion, somnolence). The COMT inhibitors entacapone and tolcapone prolong and potentiate the levodopa effect by preventing its degradation. MAO-B inhibitors also prevent the degradation of levodopa by blocking its catabolism. There are three available MAO-B inhibitors: rasagiline, safinamide, and selegiline. Both rasagiline and safinamide have demonstrated consistent efficacy in reducing motor complications in combination with levodopa/carbidopa, but the clinical benefit of selegiline appears to be relatively mild. Nourianz is a first-in-class adenosine receptor antagonist that appears to have similar efficacy and safety to other treatment options for this indication. Inbrija provides an additional therapy option of supplemental doses of levodopa when the patient notices an “off” episode beginning.

The American Academy of Neurology guidelines for the treatment of Parkinson disease with motor fluctuations and dyskinesia were published in 2006, prior to the approval of Xadago, Inbrija, Nourianz, Kynmobi, or Ongentys. These guidelines recommend that rasagiline, pramipexole, ropinirole, apomorphine (i.e., Apokyn), and tolcapone should be considered to reduce “off” time. It should be noted that tolcapone is associated with liver injury and is therefore rarely used.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Xadago, Inbrija, Nourianz, and Ongentys are each indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes. Xadago was approved in March 2017, Inbrija was approved in December 2018, Nourianz was approved in August 2019, and Ongentys was approved in April 2020.

Kynmobi was approved in May 2020 for the acute, intermittent treatment of “off” episodes in patients with Parkinson disease.

Apokyn was approved in April 2004 for the acute, intermittent treatment of hypomobility, “off” episodes in patients with advanced Parkinson disease.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

Practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Xadago
Xadago was approved based on two double-blind, placebo-controlled, 24-week studies in patients with Parkinson disease experiencing “off” time during treatment with levodopa/carbidopa. The primary efficacy endpoint in both studies was the change from baseline in total daily “on” time without troublesome dyskinesia.

Study 1 included 669 patients randomized equally to receive Xadago 50 mg/day, Xadago 100 mg/day, or placebo. Patients taking both doses of Xadago had significantly increased “on” time compared to placebo with an increase of 1.37 hours for the 50 mg dose, 1.36 hours for the 100 mg dose and 0.97 hours for the placebo.

Study 2 included 549 patients randomized equally to receive Xadago 100 mg/day or placebo. Patients taking Xadago had significantly increased “on” time compared to placebo with an increase of 1.42 hours for Xadago and 0.57 hours for placebo.

Inbrija
Inbrija was approved based on one 12-week, randomized, placebo-controlled, double-blind study in patients with Parkinson disease treated with oral carbidopa/levodopa. A total of 114 patients were randomized to receive Inbrija 84 mg (two 42 mg capsules), and 112 patients received placebo. Study medication could be administered up to five times a day. At baseline, patients had at least 2 hours per day of “off” time, and carbidopa/levodopa medication did not exceed 1600 mg levodopa per day. The mean Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores at screening in the “on” state were 14.9 for patients randomized to Inbrija 84 mg and 16.1 for patients randomized to placebo. The UPDRS part III is designed to assess the severity of the cardinal motor findings (e.g., tremor, rigidity, bradykinesia, postural instability) in patients with Parkinson disease. The primary endpoint was the change in UPDRS Part III motor score from pre-dose “off” state to 30 minutes post-dose, measured at Week 12. The average use of Inbrija or placebo was approximately 2 doses per day. At Week 12, the reduction in UPDRS Part III motor score for Inbrija vs placebo was -9.8 and -5.9, respectively. This difference from placebo of -3.92 was statistically significant with a p-value of 0.009.
The effect of Inbrija on pulmonary function was evaluated in patients with Parkinson disease treated with oral carbidopa/levodopa in a 12 month, randomized, controlled, open-labeled study. A total of 271 patients were treated with Inbrija and 127 patients were observed on their regular oral medication regimen for the treatment of Parkinson disease. Patients with chronic obstructive pulmonary disease (COPD), asthma, or other chronic respiratory disease within the last 5 years were excluded. Pulmonary function was assessed by spirometry every 3 months in both groups. After 12 months, the average reduction in the forced expiratory volume in 1 second (FEV\textsubscript{1}) from baseline was the same in both groups (-0.1 L).

Nourianz
The efficacy of Nourianz was demonstrated in four randomized, multicenter, double-blind, 12-week, placebo-controlled studies. The studies enrolled patients with a mean duration of Parkinson disease of 9 years that were Hoehn and Yahr Stage II to IV, experiencing at least 2 hours (mean approximately 6 hours) of “off” time per day, and were treated with levodopa for at least one year, with stable dosage for at least 4 weeks before screening. Patients continued levodopa treatment with or without concomitant Parkinson disease medications, provided the medications were stable for at least 4 weeks before screening and throughout the study period. The studies excluded patients who had received a neurosurgical treatment (e.g., pallidotomy, thalamotomy, deep brain stimulation). The primary efficacy endpoint was the change from baseline in the daily awake percentage of “off” time, or the change from baseline in total daily “off” time based on 24-hour diaries completed by patients.

Study 1 was conducted in the U.S. and Canada, and Study 2 was conducted in the U.S. In these studies, patients were randomized to once-daily treatment with Nourianz 20 mg, 40 mg, or placebo. Patients treated with Nourianz 20 mg or Nourianz 40 mg daily experienced a statistically significant decrease from baseline in percentage of daily awake “off” time compared with patients on placebo. For Study 1, the least squares mean difference (LSMD) between the Nourianz 40 mg group (n=129) and the placebo group (n=66) was a decrease of 6.78% awake “off” hours (p=0.007). For Study 2, the LSMD between the Nourianz 20 mg group (n=112) and the placebo group (n=113) was a decrease of 4.57% awake “off” hours (p=0.025).

Study 3 and Study 4 were conducted in Japan. In these studies, patients were randomized equally to treatment with Nourianz 20 mg, 40 mg, or placebo. Patients treated with Nourianz 20 mg or Nourianz 40 mg once daily experienced a statistically significant decrease from baseline in “off” time
compared with patients on placebo. In Study 3, the LSMD between the Nourianz 20 mg group (n=115) and the placebo group (n=118) was a decrease of 0.65 hours (p=0.028) of “off” time and the LSMD between the Nourianz 40 mg group (n=124) and the placebo group was a decrease of 0.92 hours (p=0.002) of “off” time. In study 4, the LSMD between the Nourianz 20 mg group (n=120) and the placebo group (n=123) was a decrease of 0.76 hours (p=0.006) of “off” time and the LSMD between the Nourianz 40 mg group (n=123) and the placebo group was a decrease of 0.74 hours (p=0.008).

Kynmobi
The efficacy of Kynmobi for the acute, intermittent treatment of “off” episodes in patients with Parkinson disease was established in one randomized, double-blind, placebo-controlled, parallel-group study. This study enrolled patients with a mean duration of Parkinson disease of approximately 9 years who were Hoehn and Yahr Stage III or less in the “on” state, and who were all receiving concomitant levodopa with a stable dose for at least 4 weeks before screening.

At baseline, the mean number of daily “off” episodes was 4 and the mean duration of “off” episodes was slightly over an hour in both groups. The study included a titration phase and a 12-week maintenance phase. Patients were titrated to the dose that achieved a full “on” response and was tolerated during the titration phase. Patients were treated with an oral antiemetic starting 3 days before the titration phase. In the titration phase, patients (n=141) arrived at the study site in an “off” state having not taken their regular morning dose of carbidopa/levodopa or any other adjunctive medications, as well as having taken their last dose of medication no later than midnight the night before. Treatment was initiated at the clinic with a 10 mg dose of Kynmobi. If the patient responded to treatment and tolerated the 10 mg Kynmobi dose, the patient was randomized in a blinded fashion to Kynmobi or placebo in a 1:1 ratio. If the patient tolerated the dose, but did not adequately respond, the patient was asked to return to the clinic within 3 days and the dose was increased by 5 mg. The titration process was continued up to a maximum Kynmobi dose of 35 mg or until a full “on” was achieved as determined by the investigator and the patient. Dose administration was permitted up to five times per day in the maintenance phase. The Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part III (MDS-UPDRS III) was measured pre dose, and at 15, 30, 45, 60, and 90 minutes post dose.

The primary endpoint of the study was the mean change from pre dose to 30 minutes post dose in the MDS-UPDRS III at the 12-week visit of the maintenance phase. The Kynmobi group (n=54)
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

showed a least-square mean improvement (i.e., reduction in score) of -11.1 points (95% CI: -14.9, -8.2), versus -3.5 points for the placebo group (n=55) (95% CI: -6.1, -0.9). The least-square mean treatment difference between Kynmobi and placebo was -7.6 (95% CI: -11.5, -3.7; p=0.0002).

Apokyn
The efficacy of Apokyn for the acute symptomatic treatment of recurring episodes of hypomobility, “off” episodes, in patients with advanced Parkinson disease was established in three randomized, controlled trials of Apokyn. All patients in these trials were using concomitant L-dopa at baseline, 86% were using a concomitant oral dopaminergic agonist, 31% were using a concomitant COMT inhibitor, and 10% were using a concomitant MAO-B inhibitor. Study 1 was conducted in patients who did not have prior exposure to Apokyn and studies 2 and 3 were conducted in patients with at least 3 months of Apokyn use immediately prior to study enrollment. Almost all patients without prior exposure to Apokyn began taking an antiemetic (trimethobenzamide) three days prior to starting Apokyn and 50% of patients were able to discontinue the concomitant antiemetic, on average two months after initiating Apokyn. The primary endpoint for all three studies was the change from baseline in Part III (Motor Examination) of the UPDRS.

Study 1 was a randomized, double-blind, placebo-controlled, parallel-group trial in 29 patients with advanced Parkinson disease who had at least 2 hours of “off” time per day despite an optimized oral regimen for Parkinson disease including levodopa and an oral dopaminergic agonist. Patients with atypical Parkinson disease, psychosis, dementia, hypotension, or those taking dopamine antagonists were excluded from participation. In an office setting, hypomobility was allowed to occur by withholding the patients’ Parkinson disease medications overnight. The following morning, patients (in a hypomobile state) were started on study treatment in a 2:1 ratio (2 mg of Apokyn or placebo given subcutaneously). At least 2 hours after the first dose, patients were given additional doses of study medication until they achieved a therapeutic response (defined as a response similar to the patient’s response to their usual dose of levodopa) or until 10 mg of Apokyn or placebo equivalent was given. At each injection re-dosing, the study drug dose was increased in 2 mg increments. Of the 20 patients randomized to Apokyn, 18 achieved a therapeutic response at about 20 minutes. The mean Apokyn dose was 5.4 mg. In contrast, of the 9 placebo-treated patients, none reached a therapeutic response. The mean change from baseline for the UPDRS Part III score for the Apokyn group was -23.9 which was statistically significant compared to that for the placebo (-0.1).
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

Study 2 was a randomized, placebo-controlled, crossover trial of 17 patients with Parkinson disease who had been using Apokyn for at least 3 months. Patients received their usual morning doses of Parkinson’s disease medications and were followed until hypomobility occurred, at which time they received either a single dose of subcutaneous Apokyn (at their usual dose) and placebo on different days in random order. UPDRS Part III scores were evaluated over time. The mean dose of Apokyn was 4 mg. The mean change from baseline UPDRS Part III score for the Apokyn group was -20 which was statistically significant compared to the placebo group (-3).

Study 3 used a randomized withdrawal design in 4 parallel groups from 62 patients (35 Apokyn patients and 27 placebo) with Parkinson disease who had been using Apokyn for at least 3 months. Patients were randomized to one of the following treatments dosed once by subcutaneous administration: Apokyn at the usual dose (mean dose of 4.6 mg), placebo at a volume matching the usual Apokyn dose, Apokyn at the usual dose +2 mg (mean dose 5.8 mg), or placebo at a volume matching the usual Apokyn dose + 0.2 mL. Patients received their usual morning doses of Parkinson disease medications and were followed until hypomobility occurred; at which time they received the randomized treatment. The mean change from baseline for the Apokyn group for UPDRS Part III scores at 20 minutes post dosing was -24.2 which was statistically significant compared to that for the placebo group (-7.4).

Ongentys
The efficacy of Ongentys for the adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes was evaluated in two double-blind, randomized, parallel-group studies of 14-15 week duration. Study 1 was placebo- and active-controlled and Study 2 was placebo-controlled. All patients were treated with levodopa/DOPA decarboxylase inhibitor (DDCI) alone or in combination with other Parkinson disease medications. The double-blind period for each study began with a period for levodopa/DDCI dose adjustment (up to 3 weeks) followed by a stable maintenance period of 12 weeks.

In Study 1, patients (n=600) were randomized to treatment with one of 3 doses of Ongentys. The intention to treat population included patients treated with Ongentys 50 mg once daily (n=115) or placebo (n=120). The majority (82%) of patients in both groups used concomitant Parkinson disease medication in addition to levodopa including dopamine agonists (68%), amantadine (23%), MAO-B inhibitors (20%), and anticholinergics (5%). The primary efficacy endpoint was the change in mean absolute “off” time based on 24-hour patient diaries completed 3 days prior to each of the
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

scheduled visits. Ongentys 50 mg significantly reduced mean absolute “off” time compared to placebo with a LS mean change from baseline of -0.93 hours in the placebo group and -1.95 hours in the Ongentys 50 mg group (p=0.002).

In Study 2, patients (n=427) were randomized to treatment with either one of two doses of Ongentys once daily (n=283) or placebo (n=144). The intention to treat study population included patients treated with Ongentys 50 mg once daily (n=147) or placebo (n=135). The majority in both groups used concomitant Parkinson disease medications in addition to levodopa including dopamine agonists (70%), amantadine (21%), MAO-B inhibitors (20%), and anticholinergics (12%). The primary efficacy endpoint was the change in mean absolute “off” time based on 24-hour patient diaries completed 3 days prior to each of the scheduled visits. Ongentys 50 mg significantly reduced mean absolute “off” time compared to placebo with a LS mean change from baseline of -1.07 hours in the placebo group and -1.98 hours in the Ongentys 50 mg group (p=0.008).

References

Policy History
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022
01/04/2018 Medical Policy Committee review
01/17/2018 Medical Policy Implementation Committee approval. New policy.
01/10/2019 Medical Policy Committee review

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy # 00603
Original Effective Date: 01/17/2018
Current Effective Date: 12/12/2022

07/03/2019 Medical Policy Committee review
07/18/2019 Medical Policy Implementation Committee approval. Title changed from “Xadago (safinamide)” to “Pharmacologic Treatment of Off Episodes in Parkinson Disease”. Added new drug, Inbrija, to policy with relevant background information.
02/06/2020 Medical Policy Committee review
02/12/2020 Medical Policy Implementation Committee approval. Added new drug, Nourianz, to policy with relevant background information.
02/04/2021 Medical Policy Committee review
02/10/2021 Medical Policy Implementation Committee approval. Added new drugs Ongentys and Kynmobi to policy with relevant background information.
09/02/2021 Medical Policy Committee review
09/08/2021 Medical Policy Implementation Committee approval. Added Apokyn to policy with relevant background information.
11/04/2021 Medical Policy Committee review
11/10/2021 Medical Policy Implementation Committee approval. Updated Apokyn and Kynmobi criteria to allow for trial and failure of only one generic alternative.
11/03/2022 Medical Policy Committee review

Next Scheduled Review Date: 11/2023

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Pharmacologic Treatment of Off Episodes in Parkinson Disease

Policy #  00603  
Original Effective Date:  01/17/2018  
Current Effective Date:  12/12/2022

diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.